Does Mounjaro cause hair loss?

Mounjaro is the new groundbreaking weight-loss injection recently approved in the US and UK for treating type 2 diabetes and aiding weight loss. Results from the SURMOUNT-1 trial demonstrated weight loss of up to 22.5% with the Mounjaro 15mg injection. However, the same trial also highlighted the side effects with Mounjaro, one of which was hair loss, with as many as 5.71% of the participants from the trial suffering from alopecia. In this blog we will analyse these figures in more detail to provide an answer to the question, does Mounjaro cause hair loss?

Before we explore Mounjaro and hair loss in more detail, we will first cover some basics of Mounjaro.

Use the navigational table below to skip to topics of interest.

Mounjaro and hair loss

Before you stop using Mounjaro for fear of losing your hair, we just have to put this side effect into context. From the SURMOUNT-1 trial the following results were found:

However, experiencing hair loss while on Mounjaro doesn’t mean it’s guaranteed for everyone, remember it will only occur in about 5% of people taking it. Also the research is not yet agreed on whether the hair loss is a consequence of Mounjaro itself or the result of nutrient depletion caused by the weight loss.

Nonetheless, the likelihood depends on individual factors, such as your unique response to the medication and your overall health.

Other causes for hair loss whilst on Mounjaro

It’s also important to note that not all hair loss during treatment is directly caused by Mounjaro. Common conditions like androgenetic alopecia (male pattern hair loss) or alopecia areata (an autoimmune disorder) might be unrelated to the medication. If you notice unusual hair thinning, contact us at Medical Mojo for your FREE Mounjaro weight-loss/hair loss consultation. At Medical Mojo, you have the advantage of our ability to make custom medicines to treat hair loss, combining different ingredients into topical solutions to reduce systemic side effects.

If Mounjaro is causing noticeable hair thinning, contact us or your healthcare provider. They may suggest alternatives or strategies to address this side effect. However, it’s vital not to stop or adjust your medication without medical advice.

What is androgenetic alopecia?

Androgenetic alopecia (AGA), also known as male or female pattern hair loss, is the leading cause of hair thinning and baldness, affecting at least 80% of men and half of women by age 70, with the incidence increasing with age (York, K., 2020). It is characterised by a progressive thinning of hair due to the miniaturisation of hair follicles, primarily in genetically predisposed individuals (Ho, C.H et al., 2023).

Without treatment, androgenetic alopecia can result in significant hair loss or complete baldness in certain areas, which can take a toll on emotional well-being and quality of life (York, K.,2020).

In men, androgenetic alopecia typically begins with a receding hairline and thinning at the crown, while in women, it is more diffuse, often manifesting as a widening of the central parting (Nestor, M.S.,2021).

What causes androgenetic alopecia?

The primary cause of androgenetic alopecia is the hormone dihydrotestosterone (DHT), which is converted from testosterone by an enzyme called 5-alpha reductase. DHT binds to hair follicles and disrupts their normal function, causing the hair to become thinner and eventually stop growing (Ceruti JM et al., 2018).

Over time, the hair follicles shrink, producing finer and weaker hair strands. This change in the hair growth cycle results in shorter hairs that may eventually stop growing altogether (Randall VA., 2008).

Understanding 5-alpha reductase enzymes

The 5-alpha reductase enzyme has three types:

• Type 1 – Found in the skin and hair follicles.
• Type 2 – Found in the scalp and prostate.
• Type 3 – Present in actively growing hair follicles (Asada et al., 2001).

Treatments for androgenetic alopecia

Medications like dutasteride and finasteride work by blocking the activity of these enzymes, reducing DHT levels and slowing hair loss.

To learn more about these enzyme blockers, read our blogs:

What is dutasteride?

How long does it take finasteride to start working?

How to reduce the side effects of finasteride

In addition to these 5-alpha reductase enzyme blockers, minoxidil is a drug that encourages hair growth. You can read more about minoxidil in our blog:

What is Minoxidil?

Where can I buy dutasteride and finasteride for hair loss?

If you’re noticing the early signs of male pattern baldness—such as thinning hair or receding hairlines—it’s best to act quickly for the best results.

You can purchase finasteride and dutasteride tablets and capsules from Medical Mojo after completing a short health questionnaire.

Alternatively, try compounded solutions like finasteride or dutasteride combined with minoxidil in a hair loss solution or foam.

What is alopecia areata?

Alopecia areata is an autoimmune condition characterised by sudden, patchy hair loss that occurs when the immune system mistakenly attacks hair follicles, disrupting normal hair growth. The severity can vary, ranging from small bald patches to complete scalp or body hair loss (known as alopecia totalis and universalis, respectively) (Strazzulla, L. C., et al. (2018). While the exact cause is unknown, genetic predisposition and environmental triggers, such as stress, are thought to play a role (Villasante Fricke, A.Ce et al., 2015).

Treatments typically aim to suppress immune activity or stimulate hair regrowth, with options including topical corticosteroids, minoxidil, and immunotherapy (Pratt, C.H., et al., 2017). Recent advancements, such as Janus kinase (JAK) inhibitors, have shown promise in promoting regrowth by modulating immune pathways (Ismail FF et al., 2020).

What is Mounjaro?

Mounjaro is a popular weekly injection designed to aid in weight loss, with tirzepatide as its active ingredient. It works by reducing appetite, making it easier to adhere to a calorie-controlled diet.

Mounjaro was developed by the US pharmaceutical company Eli Lilly and was approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in November 2023 for weight loss (MHRA 2023).

Mounjaro is licensed for adults with obesity (BMI ? 30) or those who are overweight (BMI 27–30) and have a weight-related health conditions (MHRA 2023).

How does Mounjaro work?

Tirzepatide, Mounjaro’s active ingredient, helps with weight loss by regulating appetite. It increases feelings of fullness, reduces hunger, and curbs food cravings (MHRA 2023).

What makes tirzepatide unique is its combination of two gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretin hormones naturally stimulate insulin release after eating. In 2016, Lily unlocked a method to combine these two incretins to produce the world’s first “twincretin” (Bokvist, B.K. et al., 2016).

This dual mechanism enhances appetite suppression, keeps you feeling full longer, and slows stomach emptying, amplifying its effectiveness. As a result, GLP-1 and GIP work synergistically together to deliver significant weight loss outcomes (Lyons, S.A. et al., 2023).

How effective is Mounjaro?

The SURMOUNT 1 trial, a large clinical study, assessed the effectiveness of Mounjaro (tirzepatide) for weight loss in individuals with obesity (BMI ? 30 kg/m²) or those who were overweight (BMI ? 27 kg/m²) and had at least one weight-related condition, such as high blood pressure. Over the course of 72 weeks, participants taking the highest dose of Mounjaro (15 mg) achieved an average weight loss of 22.5% of their starting body weight, with nearly 90% of participants losing at least 5%.

These results are groundbreaking, showcasing weight reductions of up to 20.9% for those on the 15 mg dose of Mounjaro. This far exceeds the weight loss seen with older treatments like orlistat, which typically results in 3.0% to 8.6% weight loss. Even compared to newer GLP-1-based weight loss treatments like semaglutide, which delivers an average weight loss of 12.4% (Wilding JPH et al., 2021).

The table below provides a detailed summary of the weight loss outcomes from the SURMOUNT 1 trial.

Mounjaro weight loss table

Kilogrammes (kgs) Pounds (lbs)

Week	Tirzepatide (5mg)	Tirzepatide(10mg)	Tirzepatide (15mg)	Placebo
0	105 kg	105 kg	105 kg	105 kg
4	101 kg	100.5 kg	100 kg	104.5 kg
8	96.5 kg	95.5 kg	95 kg	104 kg
12	93.5 kg	91.5 kg	90 kg	103.5 kg
16	91.5 kg	89 kg	87 kg	103 kg
24	90 kg	86 kg	84.5 kg	102.5 kg
36	89.3 kg	84.5 kg	83 kg	102.4 kg
48	89 kg	83.5 kg	82 kg	102.4 kg
72	88.6 kg	82.6 kg	81.2 kg	102.4 kg

Studies reveal that the highest maintenance dose of Mounjaro, 15mg per week, can support weight loss of up to 22.5% of a person’s starting body weight.

Summary of total weight loss after 72 weeks with Mounjaro

• 5 mg Tirzepatide: 16.4 kg (36.1 lbs)
• 10 mg Tirzepatide: 22.4 kg (49.4 lbs)
• 15 mg Tirzepatide: 23.8 kg (52.5 lbs)
• Placebo: 2.6 kg (5.7 lbs)

Have questions about Mounjaro?

Get a FREE telephone consultation with one of our pharmacists, who will call you and help you understand what the right options are for you.

Call me about Mounjaro

What strengths of Mounjaro are available?

Mounjaro is available in pre-filled injection pens with the following strengths:

• Mounjaro 2.5mg
• Mounjaro 5mg
• Mounjaro 7.5mg
• Mounjaro 10mg
• Mounjaro 12.5mg
• Mounjaro 15mg

Mounjaro is administered once a week as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. Read our blog, “How to inject Mounjaro”, to learn how to safely administer it.

Mounjaro dosing schedule

• Initial dose: You start with the Mounjaro 2.5mg dose once a week for the first four weeks.
• Increase dose: After the first four weeks on the Mounjaro 2.5mg, you increase the dose the Mounjaro 5mg injection weekly.
• Further adjustments: If your healthcare provider advises, the dose can be gradually increased at four-week intervals, up to a maximum of Mounjaro 15mg weekly. If you need to stay at a lower for longer you can to help you adjust to the side effects.

Depending on your progress and healthcare provider’s recommendation, the dose may be increased in four-week intervals up to a maximum of 15 mg weekly.

This gradual dose escalation allows your body to adjust to the medication and helps minimise side effects. Clinical trials have shown that side effects are most likely to occur during this adjustment period as your body adapts to Mounjaro (Jastreboff et al., 2022).

When beginning Mounjaro, you’ll always start with the lowest dose of 2.5 mg Mounjaro, even if you’ve previously used Mounjaro or other weight loss injections. For example, transitioning directly from a high dose of Wegovy to a high dose of Mounjaro isn’t recommended. This is because Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, which combines both GLP-1 and GIP. The difference in active ingredients means your body might respond differently, making it important to begin with the 2.5 mg dose of Mounjaro to allow your body to adjust safely.

If you’re unsure how to switch to Mounjaro or have questions about your treatment plan, reach out for a FREE consultation. Our experienced prescribers will guide you every step of the way.

For further information about dose increases, read our blog, “Mounjaro weight-loss week by week.”

Does Mounjaro cause hair loss?

Since  Mounjaro is a relatively new medication more research is needed to fully understand its effects on hair health. However, results from the SURMOUNT-1 trial suggest that about 5% of people taking Mounjaro mat experience hair loss.

As a result of these findings, the manufacturer of Mounjaro, Lily, has included  has included hair loss as a potential side effect, when Mounjaro is used for weight management in the patient information leaflet. It is characterised as a “Common” side effect and may affect up to 1 in 10 people.

The exact mechanisms behind Mounjaro-induced hair loss are not yet fully understood. It is hypothesized that the medication may influence hormonal activity or metabolism in ways that can negatively affect hair follicles.

Another potential cause for the weight loss is nutritional deficiencies caused by rapid weight loss.

The role of vitamins and mineral in hair loss

Hair loss is a common issue that may benefit from targeted vitamin and mineral supplementation. These nutrients are essential for normal cell growth and function, and deficiencies can contribute to hair loss  (Almohanna HM et al 2019).  However, it’s important to understand which vitamins and minerals are effective for addressing hair loss before starting supplementation.

Androgenetic alopecia (AGA) and telogen effluvium (TE) are two prevalent types of hair loss. Research indicates that low levels of vitamin D are associated with these conditions, and supplementation can help improve symptoms.

For individuals with AGA or TE who also have low iron levels—more commonly seen in women—iron supplementation is recommended (Almohanna HM et al 2019). Additionally, these patients should ensure they consume adequate vitamin C to enhance iron absorption (Lane, D.J et al., 2014).

 Current evidence does not strongly support supplementation with zinc, riboflavin, folic acid, or vitamin B12 in the absence of deficiencies. Similarly, there is no substantial evidence that vitamin E or biotin supplementation helps treat AGA or TE. Furthermore, excessive levels of vitamin A or selenium have been linked to hair loss, although more research is needed to confirm the role of selenium.

Alopecia areata (AA), an autoimmune condition where the immune system attacks hair follicles, has also been associated with low vitamin D levels (Lee, S et al., 2018). Supplementing vitamin D in individuals with low levels can be beneficial. However, the role of iron and zinc supplementation in AA remains uncertain, and current evidence does not support the use of folate, B12, or biotin for treatment. Selenium’s role in alopecia areata is unclear, and supplementation is not recommended  (Almohanna HM et al 2019).

Week	Tirzepatide (5mg)	Tirzepatide(10mg)	Tirzepatide (15mg)	Placebo
0	231 lbs	231 lbs	231 lbs	231 lbs
4	222.2 lbs	221.3 lbs	220.5 lbs	230 lbs
8	212.7 lbs	210.5 lbs	209.4 lbs	229 lbs
12	206 lbs	201.6 lbs	198.4 lbs	228 lbs
16	201.6 lbs	196.2 lbs	191.8 lbs	227 lbs
24	198.4 lbs	189.6 lbs	186.2 lbs	226 lbs
36	196.8 lbs	186.3 lbs	183 lbs	225.8 lbs
48	196.2 lbs	184 lbs	180.7 lbs	225.8 lbs
72	195.3 lbs	182.1 lbs	179 lbs	225.8 lbs

Can Mounjaro help reduce hair loss?

Type 2 diabetes (T2D), a condition characterised by high blood sugar and complications like heart disease and poor circulation, may cause early vascular damage that is detectable in hair follicles. This damage could appear even before type 2 diabetes is fully developed in individuals with metabolic issues. Hair loss, particularly on the legs, has been linked to poor circulation and insulin resistance, suggesting that hair follicles might serve as an early, non-invasive marker for identifying type 2 diabetes risk. (Miranda, J.J. et al., 2016).

A large study found that African American women with type 2 diabetes (T2D) are 68% more likely to experience severe central scalp hair loss, especially if they have had T2D for over 10 years or developed it before age 50. The findings highlight the need for early screening for both conditions, as diabetes may contribute to hair loss. Further research is needed to determine if managing type 2 diabetes can reduce the risk of severe hair loss (Coogan, P.F et al., 2019).

Mounjaro and polycystic ovary syndrome (PCOS) and hair loss

Polycystic Ovary Syndrome (PCOS), a condition linked to excess male hormones (androgens) and weight gain, often contributes to Female Pattern Hair Loss (FPHL). A systematic review found that approximately 28% of women with PCOS experience FPHL, compared to just 8.8% in women without PCOS in one study  (Enrico Carmina et al., 2019).

The relationship between PCOS and hair loss underscores the importance of managing weight and hormonal imbalances to mitigate symptoms like female pattern hair loss. Additionally, combining metformin (MET), a common PCOS treatment, with tirzepatide (Mounjaro), a medication for weight loss, has been shown to be significantly more effective for weight reduction. Women using this combination therapy lost an average of 8.65 kg (19 lbs), compared to just 1.09 kg (2.4 lbs) with metformin alone (Sassin, A.M et al., 2023).

Weight loss not only addresses metabolic symptoms of PCOS but may also alleviate associated hair loss.

Obesity and hair loss

Obesity and a higher BMI has been linked to a greater severity of alopecia in men with androgenetic alopecia (Yang, C.C. et al., 2014). Excess weight and a high BMI have been linked to increased severity of hair thinning in both women with PCOS and men with androgenetic alopecia (AGA).

By promoting weight loss, Mounjaro could potentially help reduce androgen-driven hair loss in men and women while improving PCOS-related symptoms such as irregular periods and acne. Although more research will be required before this can become an established treatment.

Will stopping Mounjaro stop my hair loss?

If the hair loss is found to be caused by the drug itself, then, yes this side effect should wear out as the drug leaves the body. However, if the hair loss is a consequence of the rapid weight loss and nutritional deficiencies, then unless these are rectified the hair loss will remain or get worse.

If you are unsure whether to continue or stop Mounjaro because of hair loss, contact us for  a FREE Mounjaro weight-loss/ hair-loss consultation.

How to reduce hair loss while on Mounjaro

If you do experience any hair loss when taking Mounjaro, then you could try a few simple steps to stop the loss and promote regrowth:

• Eat a balanced diet that contains all the essential vitamins and minerals, such as vitamin D.
• Make sure you are getting enough protein in your diet to stop your body breaking down muscle instead of fat.
• Try minoxidil either on its own or with finasteride or dutasteride. At Medical Mojo, you can purchase both separately or compounded into convenient topical hair solutions and foams.
• Make sure you stay hydrated, since you will be losing water weight, refer to our blog Mounjaro weight loss week by week to learn more about water-weight.

Smoking and hair loss

Smoking is associated with hair loss since it constricts blood vessels, reducing blood flow to the hair follicles, depriving them of essential nutrients and oxygen.

It was found that men who have ever smoked are 1.8 times more likely to experience male pattern baldness (AGA) compared to those who have never smoked.

Smoking 10 or more cigarettes per day was associated with twice the likelihood of developing androgenetic alopecia compared to smoking fewer than 10 cigarettes daily (Gupta, A.K et al.,2024).

Concerned about Mounjaro and hair-loss?

If you are concerned about starting Mounjaro and are worried about hair loss, contact the prescribing team at Medical Mojo. They offer a FREE consultation service to guide you through the whole weight-loss process and are there every step of the way to make sure you achieve your weight loss goals.

In addition our team of compounding pharmacists are always on hand to advise on the best hair loss solutions and are able to combine ingredients like dutasteride and minoxidil into one handy topical solution to reduce systemic side effects.

Special offer

Are weight loss treatments making you tired, or have they led to a sudden increase in hair loss? Do you struggle with sleep?

Get a free month’s supply of one of our compounded treatments for energy, hair loss or sleep, with your first purchase of Mounjaro or Wegovy from Medical Mojo.

Claim your FREE offer

Achieving weight loss with Mounjaro and expert coaching

A recent study highlighted the value of personalised coaching in an online weight loss program. Participants who received regular coaching achieved significantly greater weight loss compared to those without, with the most impressive results occurring over 12 months. Coaching provided key support by encouraging progress tracking, accessing resources, and staying focused on goals  (Unick JL, et al., 2024)

Medical Mojo’s tailored weight loss program

At Medical Mojo, we offer a complete weight loss coaching service to help you succeed. Our rogram includes:

• Weekly check-ins: Stay motivated with regular calls to monitor progress.
• Expert guidance: Receive tailored advice to set realistic and achievable goals.
• Benefit from personalised coaching to guide you every step of the way.
• FREE needles and sharps bins to make getting started hassle-free.

Our supportive coaching program is built to empower and motivate you, ensuring you achieve sustainable, long-term weight loss.

Start your Mounjaro weight-loss journey today

Take the first step toward achieving your weight loss goals with Medical Mojo. With expert support, personalised plans, and easy access to resources, you’ll be on the path to success in no time.

Disclaimer: This content is for informational purposes only and should not replace professional medical advice.

References

1. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019 Mar;9(1):51-70.
2. Asada Y, Sonoda T, Ojiro M, Kurata S, Sato T, Ezaki T, et al. 5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro. J Clin Endocrinol Metab. 2001;86(6):2875–80.
3. Bokvist, B.K.; Coskun, T.; Cummins, R.C.; Alsina-Fernandez, J. GIP and GLP-1 Co-Agonist Compounds. U.S. Patent 947478, 25 October 2016. 
4. Enrico Carmina, Ricardo Azziz, Wilma Bergfeld, Héctor F Escobar-Morreale, Walter Futterweit, Heather Huddleston, Rogerio Lobo, Elise Olsen, Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee, The Journal of Clinical Endocrinology & Metabolism, Volume 104, Issue 7, July 2019, Pages 2875–2891,
5. Ceruti JM, Leirós GJ, Balañá ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122–33.
6. Coogan, P.F., Bethea, T.N., Cozier, Y.C., Bertrand, K.A., Palmer, J.R., Rosenberg, L. and Lenzy, Y., 2019. Association of type 2 diabetes with central-scalp hair loss in a large cohort study of African American women. International Journal of Women’s Dermatology, 5(4), pp.261-266.
7. Gupta, A.K., Bamimore, M.A. and Talukder, M., 2024. A meta?analysis study on the association between smoking and male pattern hair loss. Journal of Cosmetic Dermatology, 23(4), pp.1446-1451.
8. Ho, C.H.; Sood, T.; Zito, P.M. Androgenetic Alopecia. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023
9. Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata – a promising new dawn? Expert Rev Clin Pharmacol. 2020 Jan;13(1):43-51. 
10. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C. and Stefanski, A., 2022. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), pp.205-216.
11. Lane, D.J. and Richardson, D.R., 2014. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption!. Free radical biology and medicine, 75, pp.69-83.
12. Lee, S., Kim, B.J., Lee, C.H. and Lee, W.S., 2018. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta?analysis. Journal of the European Academy of Dermatology and Venereology, 32(7), pp.1214-1221.
13. Lyons, S.A. and Beaudry, J.L., 2023. Synergistic Combinations of Gut-and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases. Endocrinology, 164(11), p.bqad153.
14. MHRA, 2023. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss. GOV.UK. Available at: https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss 
15. Miranda, J.J., Taype-Rondan, A., Tapia, J.C., Gastanadui-Gonzalez, M.G. and Roman-Carpio, R., 2016. Hair follicle characteristics as early marker of type 2 diabetes. Medical hypotheses, 95, pp.39-44.
16. National Library of Medicine. (n.d.). Study of tirzepatide (LY3298176) once weekly versus placebo in participants without diabetes who have obesity or are overweight with weight-related comorbidities (SURMOUNT-1). ClinicalTrials.gov. Retrieved December 7, 2024, from https://clinicaltrials.gov/study/NCT04184622?term=NCT04184622&rank=1&tab=results
17. Nestor, M.S., Ablon, G., Gade, A., Han, H. and Fischer, D.L., 2021. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of cosmetic dermatology, 20(12), pp.3759-3781.
18. Pratt, C.H., King, L.E., Messenger, A.G., Christiano, A.M. and Sundberg, J.P., 2017. Alopecia areata. Nature reviews Disease primers, 3(1), pp.1-17.
19. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–28.
20. Sassin, A.M., Sangi-Haghpeykar, H., Aagaard, K.M. and Detti, L., 2023. EFFECTS OF METFORMIN ALONE VERSUS METFORMIN AND TIRZEPATIDE ON WEIGHT LOSS IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS). Fertility and Sterility, 120(4), p.e222.
21. Strazzulla, L.C., Wang, E.H.C., Avila, L., Sicco, K.L., Brinster, N., Christiano, A.M. and Shapiro, J., 2018. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. Journal of the American Academy of Dermatology, 78(1), pp.15-24.
22. Trüeb, R. M. (2015). Molecular mechanisms of androgenetic alopecia. Experimental Dermatology, 24(5), 395-396.
23. Unick, J.L., Pellegrini, C.A., Dunsiger, S.I., Demos, K.E., Thomas, J.G., Bond, D.S., Lee, R.H., Webster, J. and Wing, R.R., 2024. An Adaptive Telephone Coaching Intervention for Patients in an Online Weight Loss Program: A Randomized Clinical Trial. JAMA Network Open, 7(6), pp.e2414587-e2414587.